Shimada Kazuaki, Sano Tsuyoshi, Sakamoto Yoshihiro, Kosuge Tomoo
Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Ann Surg Oncol. 2006 Dec;13(12):1569-78. doi: 10.1245/s10434-006-9143-4.
The clinical implications of combined portal vein resections are controversial.
One-hundred and forty-nine consecutive patients underwent macroscopically curative pancreatectomies for pancreatic head carcinoma between January 1, 1996 and December 31, 2004. Portal vein resection was performed in 86 patients (58%). Data on surgical mortality, morbidity, perioperative outcome, pathological factors, initial recurrence site, and survival were retrospectively compared between the patients with and without portal vein resection.
The incidence of postoperative pancreatic fistula was lower among patients who underwent portal vein resection. The median survival period was 14 months for the portal vein resection group and 35 months for the non-portal vein resection group, respectively. Combined portal vein resection was a significant predictor of poor survival using a multivariate analysis. Portal vein resection was strongly associated with larger tumor size, the degree of retropancreatic tissue invasion, the presence of extrapancreatic nerve plexus invasion, lymph node metastases, and positive cancer infiltration at the surgical margins.
Portal vein resection at the time of pancreaticoduodenectomy can be safely performed. However, most of patients requiring portal vein resection do not achieve a potentially curative resection or a favorable survival term. As a result, the aggressive application and the strict selection of portal vein resection might reduce the incidence of positive surgical margins, enabling long-term survival in patients who do not require portal vein resection.
联合门静脉切除的临床意义存在争议。
1996年1月1日至2004年12月31日期间,149例连续患者因胰头癌接受了宏观上根治性的胰腺切除术。86例患者(58%)进行了门静脉切除。对门静脉切除组和未进行门静脉切除组患者的手术死亡率、发病率、围手术期结果、病理因素、初始复发部位和生存率进行回顾性比较。
接受门静脉切除的患者术后胰瘘发生率较低。门静脉切除组的中位生存期分别为14个月,非门静脉切除组为35个月。多因素分析显示,联合门静脉切除是生存不良的重要预测因素。门静脉切除与肿瘤体积较大、胰后组织侵犯程度、胰外神经丛侵犯、淋巴结转移以及手术切缘癌浸润阳性密切相关。
胰十二指肠切除术时可安全地进行门静脉切除。然而,大多数需要门静脉切除的患者无法实现潜在的根治性切除或获得良好的生存期。因此,积极应用和严格选择门静脉切除可能会降低手术切缘阳性的发生率,使不需要门静脉切除的患者获得长期生存。